ACA
OKUR

Acorn Capital Advisors’s OnKure Therapeutics OKUR Stock Holding History

Acorn Capital Advisors’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Hold
2,839,674
– – 3.53% 9
2026
Q1 		$11.8M Hold
2,839,674
– – 3.34% 8
2025
Q4 		$8.24M Hold
2,839,674
– – 2.79% 11
2025
Q3 		$7.81M Hold
2,839,674
– – 3.96% 8
2025
Q2 		$6.79M Buy
2,839,674
+1,400,000
+97% +$3.67M 4.44% 8
2025
Q1 		$5.12M Hold
1,439,674
– – 3.42% 10
2024
Q4 		$10.2M Buy
+1,439,674
New +$21.8M 5.51% 8

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Acorn Capital Advisors's OKUR Position: Q2 2026 in Review

Acorn Capital Advisors held its OnKure Therapeutics (OKUR) position steady in Q2 2026 at 2,839,674 shares worth $12.9M. The position accounts for 3.53% of the portfolio, ranked #9.

Acorn Capital Advisors first reported a position in OKUR in Q4 2024 and has held it in 7 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Acorn Capital Advisors held 2,839,674 shares of OnKure Therapeutics worth $12.9M as of Q2 2026.
  • Acorn Capital Advisors left its OnKure Therapeutics share count unchanged in Q2 2026.
  • OnKure Therapeutics made up 3.53% of Acorn Capital Advisors's portfolio in Q2 2026, its #9 holding.
  • Acorn Capital Advisors first reported a position in OnKure Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.